This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00568984
First received: December 4, 2007
Last updated: February 17, 2017
Last verified: February 2017
  Purpose
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

Condition Intervention Phase
Diabetes Diabetes Mellitus, Type 2 Drug: repaglinide Drug: metformin Drug: glicazide Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c [ Time Frame: after 16 weeks of treatment ]

Secondary Outcome Measures:
  • Glucose profiles
  • Quality of life assessment
  • Treatment satisfaction
  • Hypoglycaemic events
  • Adverse events

Enrollment: 324
Actual Study Start Date: November 21, 2002
Study Completion Date: November 10, 2003
Primary Completion Date: November 10, 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes for at least 3 months
  • No previous treatment for diabetes
  • HbA1c between 7.0-12.0%
  • Body Mass Index (BMI) between 19.0-40.0 kg/m2

Exclusion Criteria:

  • Type 1 diabetes
  • Known unstable/untreated proliferative retinopathy
  • Uncontrolled treated/untreated hypertension
  • Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568984

Locations
China, Beijing
Novo Nordisk Investigational Site
Beijing, Beijing, China, 100034
Novo Nordisk Investigational Site
Beijing, Beijing, China, 100044
Novo Nordisk Investigational Site
Beijing, Beijing, China, 100730
China, Tianjin
Novo Nordisk Investigational Site
Tianjin, Tianjin, China, 300052
Malaysia
Novo Nordisk Investigational Site
Cheras, Malaysia, 56000
Novo Nordisk Investigational Site
Ipoh, Malaysia, 30450
Novo Nordisk Investigational Site
Kota Bharu, Kelantan, Malaysia, 16150
Philippines
Novo Nordisk Investigational Site
Cebu City, Philippines, 6000
Novo Nordisk Investigational Site
Manila, Philippines, 1003
Novo Nordisk Investigational Site
Marikina City, Philippines, 1800
Novo Nordisk Investigational Site
Pampanga, Philippines, 2000
Novo Nordisk Investigational Site
Quezon City, Philippines, 1100
Novo Nordisk Investigational Site
Quezon, Philippines, 4301
Thailand
Novo Nordisk Investigational Site
Bangkok, Thailand, 10300
Novo Nordisk Investigational Site
Bangkok, Thailand, 10330
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00568984     History of Changes
Other Study ID Numbers: AGEE-3017
Study First Received: December 4, 2007
Last Updated: February 17, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Repaglinide
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 20, 2017